Pharmacokinetics, biodistribution, and biosafety of PEGylated gold nanoparticles in vivo
Kozics, Katarina (Biomedical Research Center SAS (Bratislava, Eslovàquia). Department of Nanobiology)
Sramkova, Monika (Biomedical Research Center SAS (Bratislava, Eslovàquia). Department of Nanobiology)
Kopecka, Kristina (Biomedical Research Center SAS (Bratislava, Eslovàquia). Department of Nanobiology)
Begerova, Patricia (Biomedical Research Center SAS (Bratislava, Eslovàquia). Department of Nanobiology)
Manova, Alena (Slovak University of Technology in Bratislava. Institute of Analytical Chemistry)
Krivosikova, Zora (Slovak Medical University in Bratislava. Department of Clinical and Experimental Pharmacotherapy)
Sevcikova, Zuzana (University of Veterinary Medicine and Pharmacy in Kosice. Department of Morphological Disciplines)
Liskova, Aurelia (Slovak Medical University in Bratislava. Laboratory of Immunotoxicology)
Rollerová, Eva (Slovak Medical University in Bratislava. Laboratory of Toxicology)
Dubaj, Tibor (Slovak University of Technology in Bratislava. Institute of Physical Chemistry and Chemical Physics)
Puntes, Víctor (Institut Català de Nanociència i Nanotecnologia)
Wsolova, Ladislava (Slovak Medical University in Bratislava. Laboratory of Toxicology)
Šimon, Peter (Slovak University of Technology in Bratislava. Institute of Physical Chemistry and Chemical Physics)
Tulinska, Jana (Slovak Medical University in Bratislava. Laboratory of Immunotoxicology)
Gabelova, Alena (Biomedical Research Center SAS. Department of Nanobiology)

Data:	2021
Resum:	Despite the obvious advantages of gold nanoparticles for biomedical applications, controversial and incomplete toxicological data hamper their widespread use. Here, we present the results from an in vivo toxicity study using gold nanoparticles coated with polyethylene glycol (PEG-AuNPs). The pharmacokinetics and biodistribution of PEG-AuNPs were examined in the rat's liver, lung, spleen, and kidney after a single i. v. injection (0. 7 mg/kg) at different time intervals. PEG-AuNPs had a relatively long blood circulation time and accumulated primarily in the liver and spleen, where they remained for up to 28 days after administration. Increased cytoplasmic vacuolation in hepatocytes 24 h and 7 days after PEG-AuNPs exposure and apoptotic-like cells in white splenic pulp 24 h after administration has been detected, however, 28 days post-exposure were no longer observed. In contrast, at this time point, we identified significant changes in lipid metabolism, altered levels of liver injury markers, and elevated monocyte count, but without marked biological relevance. In blood cells, no DNA damage was present in any of the studied time intervals, with the exception of DNA breakage transiently detected in primary kidney cells 4 h post-injection. Our results indicate that the tissue accumulation of PEG-AuNPs might result in late toxic effects.
Ajuts:	European Commission 857381 European Commission 685817
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Gold nanoparticles ; Rats ; Pharmacokinetics ; Biodistribution ; Histopathology ; Clinical chemistry ; Hematology
Publicat a:	Nanomaterials, Vol. 11, issue 7 (July 2021) , art. 1702, ISSN 2079-4991

DOI: 10.3390/nano11071702
PMID: 34203551

17 p, 4.0 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències > Institut Català de Nanociència i Nanotecnologia (ICN2)
Articles > Articles de recerca
Articles > Articles publicats